Evidence map›Paper›PMID 39612651›Full record

ArticleEBioMedicine2024

Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants.

Lok Bahadur Shrestha, Katie Tungatt, Anupriya Aggarwal, Aija Stubis, Nicole L Fewings, Christina Fichter, Anouschka Akerman, Chaturaka Rodrigo, Nicodemus Tedla, Sharon Lee and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lok Bahadur ShresthaThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia.
Katie TungattCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia.
Anupriya AggarwalThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Aija StubisCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia.
Nicole L FewingsCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia.
Christina FichterThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Anouschka AkermanThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Chaturaka RodrigoSchool of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia.
Nicodemus TedlaSchool of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia.
Sharon LeeResearch & Education Network, Western Sydney Local Health District, Westmead, NSW, Australia.
Andrew R LloydThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Fabienne BrilotKids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Warwick J BrittonCentenary Institute, The University of Sydney, Camperdown, NSW, Australia; RPAH Vaccination Centre, Sydney Local Health District, Sydney, NSW, Australia.
Anthony KelleherThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Ian D CatersonRPAH Vaccination Centre, Sydney Local Health District, Sydney, NSW, Australia.
Mark W DouglasSydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; Storr Liver Centre, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australia.
Rebecca RockettSydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Stuart G TangyeGarvan Institute of Medical Research, Darlinghurst, NSW, Australia; School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
James A TriccasSydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Stuart G TurvilleThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Kerrie J SandgrenCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Rowena A BullThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia.
Anthony L CunninghamCentre for Virus Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia; Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. Electronic address: tony.cunningham@sydney.edu.au.
VIIM Collaborative Research Group of NSW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent literature informs us that bivalent vaccines will generate a broader serum neutralizing antibody response to multiple SARS-CoV-2 variants, but studies on how this breadth relates to the memory B cell (MBC) and T cell responses are sparse. This study compared breadth of neutralising antibody, and memory B and T cell responses to monovalent or a bivalent ancestral/Omicron BA.1 COVID-19 booster vaccine.

methodsAt baseline and 1-month post-booster, neutralisation activity and frequencies of receptor binding domain (RBD)-specific MBCs and Spike-specific memory T cells were measured against a panel of variants.

findingsBoth vaccines boosted neutralising antibodies to 5 variants - Wuhan-Hu-1, Delta, BA.1, BA.5 and JN.1, the latter of which had not yet emerged at the time of sample collection. The bivalent vaccine induced a significantly larger increase in nAb against BA.1 and JN.1. Both vaccines boosted RBD-specific MBC responses to Wuhan-Hu-1, Delta, BA.1 and BA.5 variants with a significantly greater increase for BA.1 in the bivalent group. The breadth of MBCs was significantly higher in those who received the bivalent boost and correlated with nAb breadth. Both vaccines significantly boosted Spike-specific T cell responses to the Wuhan-Hu-1 and BA.5 variants, but only the bivalent vaccine boosted BA.1 responses.

interpretationThese results suggest that the bivalent vaccine confers an advantage against future novel variants due to increased frequency of broadly reactive RBD-specific B cells.

fundingWork supported by NSW Health for the NSW Vaccine, Infection and Immunology Collaborative (VIIM).

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesImmunization, SecondaryMemory B CellsSARS-CoV-2Spike Glycoprotein, CoronavirusAdultB-LymphocytesFemaleHumansImmunologic MemoryMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Bivalent vaccineJN.1Memory B cellsOmicron BA.1Receptor binding domain

Identifiers

PMID39612651
PMCPMC11647467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.